N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review
Oliver G, Dean O, Camfield D, Blair-West S, Ng C, Berk M, Sarris J. N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review. Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):12-24. doi: 10.9758/cpn.2015.13.1.12. PMID: 25912534; PMCID: PMC4423164.
-
- 4 clinical trials, 5 case reports/series.
- NAC (2,400-3,000 mg/day) showed symptom reduction and good tolerability.
- 3 ongoing trials for OCD (2 adult, 1 pediatric) and 1 for excoriation.
- Conclusions: Promising results from pilot studies, with potential for future research.